# Osimertinib efficacy and evolving NSCLC treatment trends

> Live situation record from CLSTR: https://clstr.news/situations/osimertinib-efficacy-in-lung-cancer-treatment
> Updated: 2026-09-21T13:17:00.000Z. Sources: 18. Developments: 4.

Updated data from the Phase III ADAURA study, presented at the World Conference on Lung Cancer in Seoul, indicates that osimertinib provides sustained and clinically significant overall survival benefits for patients with early-stage non-small cell lung cancer (NSCLC) harboring EGFR mutations.

The eight-year data shows that in the primary analysis population (stages II–IIIA), the drug reduced the risk of death by 47% compared to a placebo, with a 74% survival rate. In the overall population (stages IB–IIIA), the risk of death was reduced by 48%, with a 79% survival rate at the eight-year mark compared to 64% for the placebo group.

Antonio Passaro, director of the thoracic oncology division at the European Institute of Oncology (IEO) in Milan, noted that patients show improved disease control and survival rates even after discontinuing treatment. This precision medicine approach represents a substantial shift from traditional adjuvant chemotherapy, which has historically offered limited long-term benefits of approximately 5-6% following radical surgery. EGFR mutations affect roughly 15% of NSCLC patients globally.

Recent developments suggest treatment paradigms for first-line EGFR-mutated advanced NSCLC are shifting toward intensified regimens. Medical experts note a transition from single-agent tyrosine kinase inhibitor (TKI) therapy to combination options to improve overall survival. Clinical findings indicate that combining the novel agent tegavivint with osimertinib shows early therapeutic activity in treatment-naive patients, aiming to target complex resistance pathways that often limit standard monotherapies.

In Italy, the long-term efficacy of the ADAURA study continues to be highlighted as a major milestone for precision medicine. This research is being recognized alongside broader national health initiatives, such as the ‘La Prevenzione è il nostro Capolavoro’ campaign, which focuses on cancer prevention and mortality reduction.

## Timeline

### 2026-09-21: Italy advances cancer prevention and oncology treatments

Italy marks major oncology milestones, including the launch of a national breast cancer prevention campaign, Andos' 50th anniversary, and significant long-term survival data for EGFR-mutated lung cancer.

14 sources. https://clstr.news/cluster/osimertinib-shows-significant-8-year-results-for-egfr-mutated-lung-cancer

### 2026-09-21: EGFR-mutated NSCLC treatment shifts toward combination therapies

Treatment for EGFR-mutated non-small cell lung cancer is moving toward intensified combination therapies, including new research into tegavivint and osimertinib to combat drug resistance.

2 sources. https://clstr.news/cluster/egfr-mutated-nsclc-treatment-shifts-toward-combination-therapies

### 2026-09-15: Osimertinib shows sustained survival benefits in lung cancer study

Eight-year ADAURA study data shows osimertinib significantly improves overall survival in patients with early-stage EGFR-mutated non-small cell lung cancer.

2 sources. https://clstr.news/cluster/osimertinib-shows-sustained-survival-benefits-in-lung-cancer-study

### 2026-08-31: Savolitinib and osimertinib combination improves lung cancer survival in trial

A phase 3 trial in China found that combining savolitinib and osimertinib significantly improves progression-free survival for patients with EGFR-mutant, MET-overexpressing non-small cell lung cancer.

2 sources. https://clstr.news/cluster/savolitinib-and-osimertinib-combination-improves-lung-cancer-survival-in-trial

---
Cite as: Osimertinib efficacy and evolving NSCLC treatment trends. CLSTR, https://clstr.news/situations/osimertinib-efficacy-in-lung-cancer-treatment